Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 31 - Medicinal preparations containing organic active ingredients
Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
10/2009
10/27/2009US7608620 inhibitors of lysophosphatidic acid acyltransferase beta (LPAAT- beta ) activity; cancer screening therapy
10/27/2009US7608619 [{4-[(4-benzyl-5-pyrrolidin-1-yl-oxazol-2-yl)-piperidin-1-yl-methyl]-cyclohexyl}-(4-fluorophenyl)-methyl]-dimethylamine; depression, urinary incontinence, diarrhoea, pruritus, alcohol and drug misuse, drug dependency, acute pain, neuropathic pain or chronic pain and anxiety
10/27/2009US7608618 1-(2,2,2-trifluoroethanoyl)pyrrolidine-2-carboxylic acid [4-methoxy-3-(3-pyrazin-2-yl-ureido)phenyl]-amide; 4-Methoxy-N-(3-methylamino-propyl)-3-(3-pyrazin-2-yl-ureido)-benzamide; checkpoint kinase Chk1 inhibitor; chemosensitizing agents useful in the treatment of diseases related to DNA damage
10/27/2009US7608617 N,N-alkylene-6-(piperidin-1-ylalkoxy)naphthalene-2-carboxamide derivatives, e.g., piperidin-1-yl-[6-(3-piperidin-1-yl-propoxy)-naphthalen-2-yl]-methanone and 3,4-dihydro-1H-isoquinolin-2-yl)-[6-(3-piperidin-1-yl-propoxy)-naphthalen-2-yl]-methanone; especially for treating obesity
10/27/2009US7608616 Methods for reducing the risk of an adverse drug interaction in a patient suffering from insomnia
10/27/2009US7608615 Pyrrolo[2,1-C][1,4]benzodiazepine hybrids and a process for the preparation thereof
10/27/2009US7608614 Halogenation and sulfonation of a 4-hydroxy-quinolone, ring closing metathesis with 2nd generation Hoveyda's catalyst of 2-(2-(cyclopropyl-2-propenyl)aminocarbonyl)-4-hydroxy-5-alkenoyl) pyrrolidine, etherification with the quinolone; one pot process; Hepatitis C viricides
10/27/2009US7608613 Soluble 17-amino-analogs of geldanamycin in acid addition salt form; water solubility; anticancer agents; storage stability
10/27/2009US7608612 potentiating radiotherapy of lung cancer treatment by administering 4(5)-nitro-L-histidine to increase anticarcinogenic agent synergistic effect
10/27/2009US7608611 18,21-didehydro-18,21-dideoxo-18,21-dihydroxy-geldanamycin derivatives as anticarcinogenic agent; with a metal chelating agent
10/27/2009US7608610 Transdermal formulation containing androgen, macrocyclic ester or ketone enhancer and thickener; extended time high blood serum concentration; rapidly absorbed gel; treatment of male hypogonadism
10/27/2009US7608609 Pharmaceutical composition
10/27/2009US7608608 Pharmaceutical composition
10/27/2009US7608607 Pharmaceutical composition
10/27/2009US7608606 Transdermal formulation containing androgen, macrocyclic ester or ketone enhancer and thickener; extended time high blood serum concentration; rapidly absorbed gel; treatment of male hypogonadism
10/27/2009US7608605 Transdermal formulation containing androgen, macrocyclic ester or ketone enhancer and thickener; extended time high blood serum concentration; rapidly absorbed gel; treatment of male hypogonadism
10/27/2009US7608604 Antiparasitic agents
10/27/2009US7608603 preferential enzyme inhibitors comprising fused pyrazolo pyrimidine derivatives used for treating arthritis, Crohns disease, irritable bowel syndrome, adult respiratory distress syndrome, or chronic obstructive pulmonary disease
10/27/2009US7608602 Beta -1-(4-Allyloxycarbonylamino-2-oxo-1H-pyrimidin-1-yl)-2-deoxy-2,2-difluororibose, for example; for treating or preventing diseases or disorders such as cancer or viral infections
10/27/2009US7608601 4′-Substituted nucleoside derivatives as inhibitors of HCV RNA replication
10/27/2009US7608600 Modified 2′ and 3′-nucleoside prodrugs for treating Flaviviridae infections
10/27/2009US7608599 (S)-2-{[(2R,3S,4R,5R)-5-(4-Amino-2-oxo-2H-pyrimidin-1-yl)-2-azido-3,4-dihydroxy-tetrahydro-furan-2-ylmethoxy]-phenoxy-phosphorylamino}-3-phenyl-propionic acid ethyl ester, for example; treatment of Hepatitis C Virus (HCV) mediated diseases
10/27/2009US7608598 Use of lipid conjugates in the treatment of conjunctivitis
10/27/2009US7608597 For therapy and prophylaxis of a Hepatitis C virus infection in a host
10/27/2009US7608596 10-substituted macrolide antibiotics
10/27/2009US7608595 4″-deoxy-4″-(S)-amido avermectin derivatives
10/27/2009US7608594 7-((2R,3R,4S,5R)-3,4-dihydroxy-5-methoxy-6,6-dimethyl-tetrahydro-2H-pyran-2-yloxy)-2H -chromen-2-one, for example; neuroprotective agents
10/27/2009US7608593 Resin composition with biodegradable non-liquid-crystalline and liquid-crystalline polymers
10/27/2009US7608592 HCV inhibitors
10/27/2009US7608585 Brain-derived neurotrophic factor (BDNF) and antioxidant Neu 2000 which is 2-hydroxy-5-(2,3,5,6-tetrafluoro-4-trifluoromethylbenzylamino)benzoic acid; synergistic; neuroprotectant
10/27/2009US7608579 Lung volume reduction using glue compositions
10/27/2009US7608578 Injecting a biocompatible bulking material such as collagen, elastin or fibrin submucosally or intramuscularly into pyloric area of the stomach to cause the lumen of pylorus to narrow and slow gastric emptying
10/27/2009US7608577 Peptidyl ketones as inhibitors of DPIV
10/27/2009US7608436 Heating an aqueous feed composition that comprises monosaccharide or linear saccharide oligomer and has a solids concentration of at least about 70% with a catalyst that accelerates the rate of cleavage or formation of glucosyl bonds; reduced content of easily digestible carbohydrates
10/27/2009US7608422 Gene therapy; vaccines; inducing antibodies and/or cytotoxic or helper T lymphocytes
10/27/2009US7608286 Phyto-nutraceutical synergistic composition for hyperlipedemic condition
10/27/2009US7608282 Transdermal granisetron
10/27/2009US7608281 Retinoic acid receptors (RAR); tissue engineering, cartilage formation; for treatment of cartilage degenerative disease, skeletal trauma; bone morphogenetic protein (BMP), osteogenic protein (OP)
10/27/2009US7608262 Such as antibodies; treating acute mycocardial infarction, deep vein thrombosis, stroke and thrombophlebitis
10/27/2009US7608257 Using a reovirus and chemotherapeutic agents to treat ras-activated neoplastic cells; proliferative disorders
10/27/2009US7608255 Replication-competent anti-cancer vectors
10/27/2009US7608253 end-capped polyethylene glycol carbamate derivatives useful as water-soluble pro-drugs; controll hydrolytic degradation of hydrogels; conjugate polymer drug for controlled release
10/27/2009US7608245 Transmission and, or amplification of signal ; oral or enteric administering; dissolving; absorption by small inteestines; peptide yy; obesity therapy
10/27/2009US7608244 benz[e]indole derivatives that absorb and fluoresce in the visible region of light, particularly useful for optical diagnosis of renal and cardiac diseases and for estimation of blood volume in vivo; low molecular weight compounds; non-immunogenic
10/27/2009CA2576232C Neuroprotective properties of dextrorotatory morphinans
10/27/2009CA2567935C Aminopyridine derivatives as selective dopamine d3 agonists
10/27/2009CA2564020C 6-o-substituted ketolides having antibacterial activity
10/27/2009CA2536886C Crystal of 1-methyl carbapenem compound
10/27/2009CA2536870C Phenyl or pyridyl amide compounds as prostaglandin e2 antagonists
10/27/2009CA2520813C Sustained release formulations of alkylene dioxybenzene derivatives useful as 5-ht1a agonists
10/27/2009CA2516400C Intranasal formulation of rotigotine
10/27/2009CA2511664C 4',4''-substituted 3.alpha.-(diphenylmethoxy)tropane analogs for treatment of mental disorders
10/27/2009CA2506441C 5-substituted-pyrazine or pyridine glucokinase activators
10/27/2009CA2494234C Methods and dosage forms for controlled delivery of paliperidone
10/27/2009CA2493359C Novel polymorph of n-methyl-n-(3-{3-[2-thienylcarbonyl]-pyrazol-[1,5-.alpha.]-pyrimidin-7-yl}phenyl)acetamide and compositions and methods related thereto
10/27/2009CA2477019C Use of total coumarins of cnidium fruit in preparing medicaments for treating psoriasis
10/27/2009CA2476884C Macrolides with antibacterial activity
10/27/2009CA2473393C Semi-fluorinated alkanes and their use
10/27/2009CA2471565C Use of a gsk-3beta inhibitor in the manufacture of a medicament for increasing bone formation
10/27/2009CA2466724C Benzamide and heteroarylamide as p2x7 receptor antagonists
10/27/2009CA2465534C Agents useful for reducing amyloid precursor protein and treating dementia and methods of use thereof
10/27/2009CA2454664C Cancer treatment with go6976 and its related compounds
10/27/2009CA2446435C 4-amino-5-phenyl-7-cyclobutyl-pyrrolo[2,3-d]pyrimidine derivatives
10/27/2009CA2437006C Aminotriazolopyridine derivatives as adenosine receptor ligands
10/27/2009CA2435426C Process for the preparation of (3-cyano-1h-indol-7-yl)(4-(4-fluorophenethyl)piperazin-1-yl)-methanone and salts thereof
10/27/2009CA2432713C Aniline derivatives or salts thereof and cytokine production inhibitors containing the same
10/27/2009CA2430318C Powder formulation and method for producing the same
10/27/2009CA2422210C Substituted imidazoles as dual histamine h1 and h3 agonists or antagonists
10/27/2009CA2421826C Substituted imidazoles as dual histamine h1 and h3 agonists or antagonists
10/27/2009CA2419666C Colonic motor dysfunction remedies
10/27/2009CA2419665C Novel 2-phenylpiperazine derivatives
10/27/2009CA2415966C Tetrahydro-heterocycloazepinyl pyrimidine derivatives
10/27/2009CA2415050C Process for the preparation of 9-amino substituted 9,10-dihydropyrrolo[2,1-b][1,3]benzothiazepines
10/27/2009CA2414584C 7-hydroxyepiandrosterone having neuroprotective activity
10/27/2009CA2410488C Methods of treating hepatitis delta virus infection with .beta.-l-2' deoxy-nucleosides
10/27/2009CA2406044C Phenylethylamines and condensed rings variants as prodrugs of catecholamines, and their use
10/27/2009CA2404514C Novel substance having physiological property, method for producing the same and uses thereof
10/27/2009CA2392741C Surfactants as malarial chloroquine resistance reversal agents
10/27/2009CA2392057C Calcium salts of 1,5-benzodiazepine derivatives, process for producing the salts and drugs containing the same
10/27/2009CA2381885C Isomeric fused pyrrolocarbazoles and isoindolones
10/27/2009CA2381165C Novel quinuclidine derivatives and medicinal compositions containing the same
10/27/2009CA2379021C New phenylpiperazines
10/27/2009CA2376355C N-heterocyclic derivatives as nos inhibitors
10/27/2009CA2372085C L-ribo-lna analogues
10/27/2009CA2365204C Lipoxin compounds and their use
10/27/2009CA2363792C Percutaneous absorption preparation of compound having angiotensin ii antagonistic activity
10/27/2009CA2361285C Propanoic acid derivatives that inhibit the binding of integrins to their receptors
10/27/2009CA2361174C 4-amino-quinazoline and quinoline derivatives having an inhibitory effect on signal transduction mediated by tyrosine kinases
10/27/2009CA2359454C ((aminoiminomethyl) amino) alkanecarboxamides and their applications in therapy
10/27/2009CA2342582C A method of inhibiting formation of infectious herpes virus particles
10/27/2009CA2341434C Pyrrolobenzodiazepine compounds
10/27/2009CA2338141C Polymer complexes of glucuronoglucanes
10/27/2009CA2322171C Cyclic amino compounds
10/27/2009CA2320900C Biphasic controlled release delivery system for high solubility pharmaceuticals and method
10/27/2009CA2319837C Hydroxylation activated drug release
10/27/2009CA2318694C Antivirals
10/27/2009CA2318145C Sulfonylamino derivatives which inhibit matrix-degrading metalloproteinases
10/27/2009CA2243474C Quinolin-2-(1h)-ones
10/27/2009CA2224143C Recombinant hexose oxidase, a method of producing same and use of such enzyme
10/27/2009CA2163364C Self-assembling polynucleotide delivery system comprising dendrimer polycations
1 ... 2525 2526 2527 2528 2529 2530 2531 2532 2533 2534 2535 2536 2537 2538 2539 2540 2541 2542 2543 2544 2545 ... 7860